Trial Profile
An Observational, Prospective Cohort Study to Evaluate the Safety and Efficacy of Remsima in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Celltrion
- 12 Jul 2021 Results of a pooled analysis assessing long-term safety and effectiveness over 5 years from three observational studies: NCT02557295, NCT02326155 and NCT02557308 published in the Advances in Therapy
- 30 Apr 2020 Results of post marketing pooled analysis of six observational studies published in the BioDrugs
- 23 Jul 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2020.